Sugi Predict

Sugi Predict / Compounds / SCHEMBL21831489

SCHEMBL21831489

SCHEMBL21831489

CN1C(=O)CC(=O)c2nc(Br)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRIM24 O15164 1/20 0.40
▸ GABRA1 P14867 1/20 0.33
▸ GABRG2 P18507 1/20 0.33
▸ GABRB3 P28472 1/20 0.33
▸ GABRA5 P31644 1/20 0.33
▸ GABRA3 P34903 1/20 0.33
▸ GABRA2 P47869 1/20 0.33
▸ GABRB2 P47870 1/20 0.33
▸ IDO1 P14902 1/20 0.33
▸ CDC25A P30304 1/20 0.33
▸ CDC25B P30305 1/20 0.33
▸ CDC25C P30307 1/20 0.33
▸ DUSP3 P51452 1/20 0.33
▸ OPRK1 P41145 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ BMPR1B O00238 4/20 0.32
▸ BMPR1A P36894 4/20 0.32
▸ ACVRL1 P37023 4/20 0.32
▸ ACVR1 Q04771 4/20 0.32
▸ TGFBR1 P36897 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29764153 1.00 TRIM24 (0.40) TRIM24GABRA1GABRG2GABRB3GABRA5
SCHEMBL29769801 0.80 TRIM24 (0.40) TRIM24CDC25ACDC25BCDC25CDUSP3
SCHEMBL23564216 0.76 TRIM24 (0.37) TRIM24GABRA1GABRG2GABRB3GABRA5
SCHEMBL30833285 0.71 CYP1A2 (0.35) TRIM24ALDH1A1
SCHEMBL30322638 0.69 HTR2A (0.37) TRIM24IDO1BMPR1BBMPR1AACVRL1
SCHEMBL30833282 0.69 TRIM24 (0.33) TRIM24CDC25ACDC25BCDC25CDUSP3
SCHEMBL760693 0.66 CCNB2 (0.37) TRIM24GABRA1GABRG2GABRB3GABRA5
SCHEMBL21603583 0.66 PKM (0.38) TRIM24GABRA1GABRG2GABRB3GABRA5
SCHEMBL29778811 0.66 PKM (0.38) TRIM24GABRA1GABRG2GABRB3GABRA5
SCHEMBL21831150 0.65 PIM1 (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081523-B1 SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2024-12-25 — — EP disclosed
US-11964973-B2 Substituted bicyclic compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-23 — — US disclosed
EP-3814348-B9 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-11-01 — — EP disclosed
WO-2023184327-A1 KINASE INHIBITORS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-10-05 — — WO disclosed
EP-3814348-B1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-08-02 — — EP disclosed
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 — — US disclosed
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 — — US disclosed
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 — — US disclosed
US-20230086933-A1 SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY 2023-03-23 — — US disclosed
EP-4081524-A1 SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS Bristol-Myers Squibb Company (US) 2022-11-02 — — EP disclosed
WO-2021133752-A1 SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-07-01 — — WO disclosed
US-20210188845-A1 SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY 2021-06-24 — — US disclosed
US-20210188845-A1 SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY 2021-06-24 — — US disclosed
EP-3814348-A1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS Bristol-Myers Squibb Company (US) 2021-05-05 — — EP disclosed
US-10954238-B1 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2021-03-23 — — US disclosed
US-10954238-B1 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2021-03-23 — — US disclosed
US-10669272-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2020-06-02 — — US disclosed
US-10669272-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2020-06-02 — — US disclosed
US-20200109140-A1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS SYNGENE INTERNATIONAL LIMITED (IN) 2020-04-09 — — US disclosed
US-20200109140-A1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS SYNGENE INTERNATIONAL LIMITED (IN) 2020-04-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200109140-A1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG TRIM24 4145/4885GABRA1 3876/4885GABRG2 3775/4885
US-20230086933-A1 SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKA, DGKG, DGKZ TRIM24 4415/4885GABRA1 3297/4885GABRG2 2632/4885
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG TRIM24 4145/4885GABRA1 3876/4885GABRG2 3775/4885
US-20210188845-A1 SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKA, DGKZ, DGKK TRIM24 4281/4885GABRA1 2743/4885GABRG2 2401/4885
US-10669272-B2 Substituted naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG TRIM24 4145/4885GABRA1 3876/4885GABRG2 3775/4885
US-11964973-B2 Substituted bicyclic compounds useful as T cell activators DGKA, DGKZ, DGKK TRIM24 4281/4885GABRA1 2743/4885GABRG2 2401/4885
US-10954238-B1 Substituted naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG TRIM24 4145/4885GABRA1 3876/4885GABRG2 3775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.